Esophageal cancer screening
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer screening On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer screening |
|
Risk calculators and risk factors for Esophageal cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Screening may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. However, no such program is in effect presently.
Screening
- There is no program in effect to screen for esophageal cancer at present, however the benefits of screening were demonstrated in a high risk population in China that showed a reduction in the incidence of esophageal cancer by 53%.[1]
- In 1983, a study was carried out in Hishun village, China.
- Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high.
- 6758 subjects were examined by esophageal exfoliative cytology, 1729 had marked dysplasia and 2411 had mild dysplasia of esophageal epithelium.
- Those with marked dysplasia were randomly divided into 3 groups and given: antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo.
- The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo.
- They took their respective treatments for 3 years and were then reexamined using cytology.
- The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%).
- The incidence of esophageal cancer in retinamide and riboflavin groups were reduced by 33.7% and 19% as compared with those of the control groups.
- These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer.[1]